Skip to main content

Market Overview

Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO

Share:
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
  • Mirati Therapeutics Inc (NASDAQ: MRTXannounced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harboring a KRASG12C mutation.
  • Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. 
  • The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
  • As of May 25, the response rate in the 45 evaluable patients who received adagrasib as monotherapy stood at 22%, including one unconfirmed partial response (PR) and a disease control rate (DCR) of 87%.
  • The median duration of response was 4.2 months, with the median progression-free survival (PFS) was 5.6 months.
  • Mirati also shared an update on patients who have received adagrasib in combination with Eli Lilly And Co's (NYSE: LLY) Erbitux (cetuximab).
  • The response rate in the 28 evaluable patients who received the combination was 43%, including two people with unconfirmed partial responses and a disease control rate of 100% at a median seven-month check-in.
  • After the July 9 data cutoff, follow-up scans confirmed one response, but the other patient progressed. 
  • There were no deaths reported in either arm of the study, and the combination arm outperformed the solo drug arm in terms of Grade 3/4 side effects with rates of 16% and 30%, respectively.
  • Price Action: MRTX stock is down 3.19% at $168.50 during the premarket session on the last check Monday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
 

Related Articles (LLY + MRTX)

View Comments and Join the Discussion!

Posted-In: Briefs colorectal cancerBiotech News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com